Castle Biosciences Stock Net Asset
| CSTL Stock | USD 19.16 0.20 1.03% |
Fundamental analysis of Castle Biosciences allows traders to better anticipate movements in Castle Biosciences' stock price by examining its financial health and performance throughout various phases of its business cycle.
Castle | Net Asset | Build AI portfolio with Castle Stock |
Castle Biosciences Company Net Asset Analysis
Castle Biosciences' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Castle Biosciences Net Asset | 531.24 M |
Most of Castle Biosciences' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Castle Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Castle Net Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Castle Biosciences is extremely important. It helps to project a fair market value of Castle Stock properly, considering its historical fundamentals such as Net Asset. Since Castle Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Castle Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Castle Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Castle Total Assets
Total Assets |
|
Based on the recorded statements, Castle Biosciences has a Net Asset of 531.24 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Castle Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Castle Biosciences' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Castle Biosciences could also be used in its relative valuation, which is a method of valuing Castle Biosciences by comparing valuation metrics of similar companies.Castle Biosciences is currently under evaluation in net asset category among its peers.
Castle Biosciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Castle Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Castle Biosciences' managers, analysts, and investors.Environmental | Governance | Social |
Castle Biosciences Institutional Holders
Institutional Holdings refers to the ownership stake in Castle Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Castle Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Castle Biosciences' value.| Shares | Geode Capital Management, Llc | 2025-03-31 | 649.9 K | Allianz Asset Management Ag | 2025-03-31 | 639.5 K | Schroder Investment Management Group | 2025-03-31 | 597.1 K | Park West Asset Management Llc | 2025-03-31 | 556.5 K | Palisade Capital Management Llc | 2025-03-31 | 490 K | Bank Of America Corp | 2025-03-31 | 375.4 K | Braidwell Lp | 2025-03-31 | 365.2 K | Parkman Healthcare Partners Llc | 2025-03-31 | 350.6 K | Ameriprise Financial Inc | 2025-03-31 | 325.7 K | Blackrock Inc | 2025-03-31 | 3 M | Vanguard Group Inc | 2025-03-31 | 2 M |
Castle Fundamentals
| Return On Equity | -0.0215 | ||||
| Return On Asset | -0.0279 | ||||
| Profit Margin | (0.03) % | ||||
| Operating Margin | (0.05) % | ||||
| Current Valuation | 316.35 M | ||||
| Shares Outstanding | 29.01 M | ||||
| Shares Owned By Insiders | 2.94 % | ||||
| Shares Owned By Institutions | 92.96 % | ||||
| Number Of Shares Shorted | 1.41 M | ||||
| Price To Earning | 87.86 X | ||||
| Price To Book | 1.22 X | ||||
| Price To Sales | 1.61 X | ||||
| Revenue | 332.07 M | ||||
| Gross Profit | 280.47 M | ||||
| EBITDA | 38.14 M | ||||
| Net Income | 18.25 M | ||||
| Cash And Equivalents | 273.17 M | ||||
| Cash Per Share | 10.39 X | ||||
| Total Debt | 26.34 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 11.08 X | ||||
| Book Value Per Share | 15.71 X | ||||
| Cash Flow From Operations | 64.87 M | ||||
| Short Ratio | 3.40 X | ||||
| Earnings Per Share | (0.34) X | ||||
| Target Price | 35.63 | ||||
| Number Of Employees | 798 | ||||
| Beta | 1.09 | ||||
| Market Capitalization | 555.8 M | ||||
| Total Asset | 531.24 M | ||||
| Retained Earnings | (200.13 M) | ||||
| Working Capital | 310.76 M | ||||
| Current Asset | 125.89 M | ||||
| Current Liabilities | 13.31 M | ||||
| Net Asset | 531.24 M |
About Castle Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Castle Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Castle Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Castle Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Castle Biosciences Piotroski F Score and Castle Biosciences Altman Z Score analysis. For more information on how to buy Castle Stock please use our How to buy in Castle Stock guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Castle Biosciences. If investors know Castle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Castle Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.52) | Earnings Share (0.34) | Revenue Per Share | Quarterly Revenue Growth (0.01) | Return On Assets |
The market value of Castle Biosciences is measured differently than its book value, which is the value of Castle that is recorded on the company's balance sheet. Investors also form their own opinion of Castle Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Castle Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Castle Biosciences' market value can be influenced by many factors that don't directly affect Castle Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Castle Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Castle Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Castle Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.